ISDA

Deposition Date 2013-09-09

Release Date 2013-11-20

Last Version Date 2024-11-20

Entry Detail

PDB ID:

4MMU

Keywords:

VIRAL PROTEIN

Title:

Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1 at pH 5.5

Biological Source:

Source Organism:

Human respiratory syncytial virus A2 (Taxon ID: 11259)
Enterobacteria phage T4 (Taxon ID: 10665)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.00 Å

R-Value Free:

0.22

R-Value Work:

0.17

R-Value Observed:

0.18

Space Group:

P 41 3 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F2
Gene (Uniprot):F
Mutations:P102A
Chain IDs:A
Chain Length:82
Number of Molecules:1
Biological Source:Human respiratory syncytial virus A2

UniProt ID:P03420 Pfam ID:PF00523

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F1 fused with Fibritin trimerization domain
Gene (Uniprot):F, wac
Mutations:S155C, S190F, V207L, S290C, I379V, M447V
Chain IDs:B
Chain Length:414
Number of Molecules:1
Biological Source:Human respiratory syncytial virus A2, Enterobacteria phage T4

UniProt ID:P03420,P10104 Pfam ID:PF00523

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
ASN	B	ASN	GLYCOSYLATION SITE

Ligand Molecules

NAG

PO4

SO4

Primary Citation

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

McLellan, J.S, Chen, M, Joyce, M.G, Sastry, M, Stewart-Jones, G.B, Yang, Y, Zhang, B, Chen, L, Srivatsan, S, Zheng, A, Zhou, T, Graepel, K.W, Kumar, A, Moin, S, Boyington, J.C, Chuang, G.Y, Soto, C, Baxa, U, Bakker, A.Q, Spits, H, Beaumont, T, Zheng, Z, Xia, N, Ko, S.Y, Todd, J.P, Rao, S, Graham, B.S, Kwong, P.D.Show

Science 342 592 598 (2013)

PMID: 24179220 DOI: 10.1126/science.1243283

Abstact

Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5 years of age. We sought to engineer a viral antigen that provides greater protection than currently available vaccines and focused on antigenic site Ø, a metastable site specific to the prefusion state of the RSV fusion (F) glycoprotein, as this site is targeted by extremely potent RSV-neutralizing antibodies. Structure-based design yielded stabilized versions of RSV F that maintained antigenic site Ø when exposed to extremes of pH, osmolality, and temperature. Six RSV F crystal structures provided atomic-level data on how introduced cysteine residues and filled hydrophobic cavities improved stability. Immunization with site Ø-stabilized variants of RSV F in mice and macaques elicited levels of RSV-specific neutralizing activity many times the protective threshold.

Legend

Protein

Chemical

Disease

Primary Citation of related structures